In early September this year, 74-year-old Ms Bao suffered an abrupt health crisis. Within just a few days, her condition deteriorated rapidly from general fatigue to acute kidney failure. The culprit was atypical hemolytic uremic syndrome (aHUS). Fortunately, thanks to precise treatment by a multidisciplinary team at Sir Robert Run Shaw Hospital, Zhejiang University School of Medicine, she was successfully weaned off dialysis on the 22nd day of onset and regained a healthy li

Excess neck fat acts like a “noose,” compressing the airway. At night, relaxed muscles cause repeated airway collapse: breathing pauses hundreds of times nightly, up to 50 seconds each — repeated cycles of hypoxia → suffocation → awakening. This intermittent nighttime hypoxia: Raises heart workload，Triggers sympathetic overactivity，Causes nocturnal hypertension and arrhythmias，Increases sudden‑death risk.

According to statistics from the Particle Therapy Co‑Operative Group (PTCOG), by 2021, more than 260,000 patients worldwide had received proton or heavy‑ion therapy. The number of proton centers grew from 1 in 1990 to over 100 today, and is still rising rapidly. Proton therapy has become a major global trend in precision cancer radiotherapy.

Recently, a delegation from Bangkok Hospital visited Jiahui Health, and the two sides held exchanges focusing on oncology diagnosis, treatment and innovation. The two sides focused on cutting-edge topics in clinical oncology – ranging from surgical operations to advanced and sophisticated therapies such as CAR-T, as well as the application practice of new anti-tumor drugs in China.

During the treatment, Dr. Chen Yan, Director of the Neurology Department at Jiahui, also addressed several Parkinson’s disease-related issues for Daniel: adjusting his medications, preventing fall risks and formulating a rehabilitation plan. These problems,which had never been properly managed during his treatment in the US, received meticulous attention at Jiahui.

Novel cell therapy shows potential: As an emerging cellular immunotherapy method, CAR-NK cell therapy can still be effective in patients who have failed CAR-T treatment. With mild CRS (cytokine release syndrome) reaction and good safety, it provides a new treatment option for refractory and relapsed patients and is expected to become an important treatment direction for such patients in the future;

Recently, the international hematology journal Blood Advances published a prospective clinical study by Lu Daopei Medical Team, titled "Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma," reporting breakthrough clinical results of BCMA-targeted nanobody-based CAR-T cell therapy in heavily pretreated refractory/relapsed plasma cell neoplasms.